nodes	percent_of_prediction	percent_of_DWPC	metapath
Salicylate-sodium—PTGS2—urinary bladder cancer	0.534	1	CbGaD
Salicylate-sodium—PTGS2—Cisplatin—urinary bladder cancer	0.0889	0.356	CbGbCtD
Salicylate-sodium—PTGS2—Etoposide—urinary bladder cancer	0.0874	0.349	CbGbCtD
Salicylate-sodium—PTGS1—Etoposide—urinary bladder cancer	0.0738	0.295	CbGbCtD
Salicylate-sodium—Acetylsalicylic acid—TP53—urinary bladder cancer	0.0018	0.303	CrCbGaD
Salicylate-sodium—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.0014	0.0505	CbGpPWpGaD
Salicylate-sodium—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—urinary bladder cancer	0.00129	0.0467	CbGpPWpGaD
Salicylate-sodium—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.00111	0.0401	CbGpPWpGaD
Salicylate-sodium—Mesalazine—MPO—urinary bladder cancer	0.00109	0.184	CrCbGaD
Salicylate-sodium—Mesalazine—PPARG—urinary bladder cancer	0.000967	0.163	CrCbGaD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00095	0.0343	CbGpPWpGaD
Salicylate-sodium—PTGS2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000754	0.0272	CbGpPWpGaD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000666	0.024	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—PTCRA—urinary bladder cancer	0.000605	0.0218	CbGpPWpGaD
Salicylate-sodium—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	0.000588	0.0212	CbGpPWpGaD
Salicylate-sodium—Magnesium salicylate—PTGS2—urinary bladder cancer	0.000553	0.0934	CrCbGaD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000505	0.0183	CbGpPWpGaD
Salicylate-sodium—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—urinary bladder cancer	0.000487	0.0176	CbGpPWpGaD
Salicylate-sodium—Salsalate—PTGS2—urinary bladder cancer	0.000471	0.0794	CrCbGaD
Salicylate-sodium—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	0.000457	0.0165	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—GSTZ1—urinary bladder cancer	0.000453	0.0164	CbGpPWpGaD
Salicylate-sodium—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	0.000446	0.0161	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—GSTO2—urinary bladder cancer	0.000429	0.0155	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—NAT1—urinary bladder cancer	0.000429	0.0155	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000429	0.0155	CbGpPWpGaD
Salicylate-sodium—Mesalazine—PTGS2—urinary bladder cancer	0.000408	0.0689	CrCbGaD
Salicylate-sodium—PTGS2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000401	0.0145	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000393	0.0142	CbGpPWpGaD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—PTGS2—urinary bladder cancer	0.000382	0.0138	CbGpPWpGaD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.00037	0.0134	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000354	0.0128	CbGpPWpGaD
Salicylate-sodium—Acetylsalicylic acid—PTGS2—urinary bladder cancer	0.000351	0.0593	CrCbGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000346	0.0125	CbGpPWpGaD
Salicylate-sodium—PTGS2—S1P1 pathway—RHOA—urinary bladder cancer	0.000335	0.0121	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000318	0.0115	CbGpPWpGaD
Salicylate-sodium—PTGS1—Eicosanoid Synthesis—PTGS2—urinary bladder cancer	0.000317	0.0114	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.000306	0.011	CbGpPWpGaD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000299	0.0108	CbGpPWpGaD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000294	0.0106	CbGpPWpGaD
Salicylate-sodium—Salicylic acid—PTGS2—urinary bladder cancer	0.000289	0.0488	CrCbGaD
Salicylate-sodium—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000265	0.00957	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—MPO—urinary bladder cancer	0.000262	0.00945	CbGpPWpGaD
Salicylate-sodium—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—urinary bladder cancer	0.000259	0.00935	CbGpPWpGaD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000258	0.00931	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000252	0.0091	CbGpPWpGaD
Salicylate-sodium—PTGS2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000237	0.00857	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—NAT2—urinary bladder cancer	0.000235	0.0085	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000208	0.00752	CbGpPWpGaD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000205	0.00739	CbGpPWpGaD
Salicylate-sodium—Convulsion—Etoposide—urinary bladder cancer	0.000201	0.00111	CcSEcCtD
Salicylate-sodium—Dehydration—Epirubicin—urinary bladder cancer	0.000201	0.00111	CcSEcCtD
Salicylate-sodium—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	0.0002	0.00723	CbGpPWpGaD
Salicylate-sodium—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.0002	0.0011	CcSEcCtD
Salicylate-sodium—Asthma—Methotrexate—urinary bladder cancer	0.000199	0.0011	CcSEcCtD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000199	0.0072	CbGpPWpGaD
Salicylate-sodium—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000199	0.0011	CcSEcCtD
Salicylate-sodium—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000198	0.00109	CcSEcCtD
Salicylate-sodium—Chest pain—Etoposide—urinary bladder cancer	0.000198	0.00109	CcSEcCtD
Salicylate-sodium—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000197	0.00109	CcSEcCtD
Salicylate-sodium—Somnolence—Gemcitabine—urinary bladder cancer	0.000197	0.00109	CcSEcCtD
Salicylate-sodium—Anorexia—Cisplatin—urinary bladder cancer	0.000197	0.00109	CcSEcCtD
Salicylate-sodium—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000197	0.00109	CcSEcCtD
Salicylate-sodium—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000196	0.00108	CcSEcCtD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000196	0.00706	CbGpPWpGaD
Salicylate-sodium—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000194	0.00107	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000194	0.00107	CcSEcCtD
Salicylate-sodium—Somnolence—Fluorouracil—urinary bladder cancer	0.000194	0.00107	CcSEcCtD
Salicylate-sodium—Hypotension—Cisplatin—urinary bladder cancer	0.000193	0.00107	CcSEcCtD
Salicylate-sodium—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000193	0.00107	CcSEcCtD
Salicylate-sodium—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000192	0.00106	CcSEcCtD
Salicylate-sodium—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Salicylate-sodium—Fatigue—Gemcitabine—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Salicylate-sodium—Confusional state—Etoposide—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.00019	0.00687	CbGpPWpGaD
Salicylate-sodium—Constipation—Gemcitabine—urinary bladder cancer	0.00019	0.00105	CcSEcCtD
Salicylate-sodium—Pain—Gemcitabine—urinary bladder cancer	0.00019	0.00105	CcSEcCtD
Salicylate-sodium—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00019	0.00105	CcSEcCtD
Salicylate-sodium—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000189	0.00105	CcSEcCtD
Salicylate-sodium—Asthenia—Thiotepa—urinary bladder cancer	0.000189	0.00105	CcSEcCtD
Salicylate-sodium—Infection—Etoposide—urinary bladder cancer	0.000188	0.00104	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—HPGDS—urinary bladder cancer	0.000188	0.00679	CbGpPWpGaD
Salicylate-sodium—Abdominal distension—Epirubicin—urinary bladder cancer	0.000188	0.00104	CcSEcCtD
Salicylate-sodium—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000187	0.00103	CcSEcCtD
Salicylate-sodium—Dysphagia—Epirubicin—urinary bladder cancer	0.000187	0.00103	CcSEcCtD
Salicylate-sodium—Asthma—Epirubicin—urinary bladder cancer	0.000187	0.00103	CcSEcCtD
Salicylate-sodium—Pruritus—Thiotepa—urinary bladder cancer	0.000187	0.00103	CcSEcCtD
Salicylate-sodium—Pain—Fluorouracil—urinary bladder cancer	0.000186	0.00103	CcSEcCtD
Salicylate-sodium—Dehydration—Doxorubicin—urinary bladder cancer	0.000186	0.00103	CcSEcCtD
Salicylate-sodium—Paraesthesia—Cisplatin—urinary bladder cancer	0.000186	0.00103	CcSEcCtD
Salicylate-sodium—Tachycardia—Etoposide—urinary bladder cancer	0.000185	0.00102	CcSEcCtD
Salicylate-sodium—Dyspnoea—Cisplatin—urinary bladder cancer	0.000184	0.00102	CcSEcCtD
Salicylate-sodium—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000183	0.00101	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000183	0.00101	CcSEcCtD
Salicylate-sodium—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000183	0.00101	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—GSTT1—urinary bladder cancer	0.000182	0.00659	CbGpPWpGaD
Salicylate-sodium—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000182	0.00101	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000182	0.00656	CbGpPWpGaD
Salicylate-sodium—Anorexia—Etoposide—urinary bladder cancer	0.000181	0.000998	CcSEcCtD
Salicylate-sodium—Diarrhoea—Thiotepa—urinary bladder cancer	0.00018	0.000997	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.00018	0.0065	CbGpPWpGaD
Salicylate-sodium—Decreased appetite—Cisplatin—urinary bladder cancer	0.00018	0.000993	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00018	0.000993	CcSEcCtD
Salicylate-sodium—Bronchitis—Epirubicin—urinary bladder cancer	0.00018	0.000992	CcSEcCtD
Salicylate-sodium—Drowsiness—Methotrexate—urinary bladder cancer	0.000178	0.000983	CcSEcCtD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.000178	0.00641	CbGpPWpGaD
Salicylate-sodium—Hypotension—Etoposide—urinary bladder cancer	0.000177	0.000978	CcSEcCtD
Salicylate-sodium—Pain—Cisplatin—urinary bladder cancer	0.000177	0.000977	CcSEcCtD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000176	0.00636	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000176	0.00634	CbGpPWpGaD
Salicylate-sodium—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000175	0.000969	CcSEcCtD
Salicylate-sodium—Renal failure—Methotrexate—urinary bladder cancer	0.000175	0.000966	CcSEcCtD
Salicylate-sodium—Dizziness—Thiotepa—urinary bladder cancer	0.000174	0.000964	CcSEcCtD
Salicylate-sodium—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000174	0.000961	CcSEcCtD
Salicylate-sodium—Urticaria—Fluorouracil—urinary bladder cancer	0.000173	0.000958	CcSEcCtD
Salicylate-sodium—Asthma—Doxorubicin—urinary bladder cancer	0.000173	0.000955	CcSEcCtD
Salicylate-sodium—Dysphagia—Doxorubicin—urinary bladder cancer	0.000173	0.000955	CcSEcCtD
Salicylate-sodium—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000172	0.000953	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00017	0.000942	CcSEcCtD
Salicylate-sodium—Paraesthesia—Etoposide—urinary bladder cancer	0.00017	0.00094	CcSEcCtD
Salicylate-sodium—Weight increased—Epirubicin—urinary bladder cancer	0.00017	0.000939	CcSEcCtD
Salicylate-sodium—Dyspnoea—Etoposide—urinary bladder cancer	0.000169	0.000933	CcSEcCtD
Salicylate-sodium—Somnolence—Etoposide—urinary bladder cancer	0.000168	0.000931	CcSEcCtD
Salicylate-sodium—Epistaxis—Methotrexate—urinary bladder cancer	0.000168	0.000927	CcSEcCtD
Salicylate-sodium—Vomiting—Thiotepa—urinary bladder cancer	0.000168	0.000927	CcSEcCtD
Salicylate-sodium—Drowsiness—Epirubicin—urinary bladder cancer	0.000166	0.00092	CcSEcCtD
Salicylate-sodium—Rash—Thiotepa—urinary bladder cancer	0.000166	0.000919	CcSEcCtD
Salicylate-sodium—Bronchitis—Doxorubicin—urinary bladder cancer	0.000166	0.000918	CcSEcCtD
Salicylate-sodium—Dermatitis—Thiotepa—urinary bladder cancer	0.000166	0.000918	CcSEcCtD
Salicylate-sodium—Headache—Thiotepa—urinary bladder cancer	0.000165	0.000913	CcSEcCtD
Salicylate-sodium—Decreased appetite—Etoposide—urinary bladder cancer	0.000165	0.00091	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000164	0.00591	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000164	0.00591	CbGpPWpGaD
Salicylate-sodium—Renal failure—Epirubicin—urinary bladder cancer	0.000164	0.000904	CcSEcCtD
Salicylate-sodium—Body temperature increased—Cisplatin—urinary bladder cancer	0.000163	0.000903	CcSEcCtD
Salicylate-sodium—Fatigue—Etoposide—urinary bladder cancer	0.000163	0.000902	CcSEcCtD
Salicylate-sodium—Constipation—Etoposide—urinary bladder cancer	0.000162	0.000895	CcSEcCtD
Salicylate-sodium—Pain—Etoposide—urinary bladder cancer	0.000162	0.000895	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000161	0.000888	CcSEcCtD
Salicylate-sodium—Hepatitis—Methotrexate—urinary bladder cancer	0.00016	0.000883	CcSEcCtD
Salicylate-sodium—Asthenia—Gemcitabine—urinary bladder cancer	0.000159	0.00088	CcSEcCtD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000158	0.00572	CbGpPWpGaD
Salicylate-sodium—Weight increased—Doxorubicin—urinary bladder cancer	0.000157	0.000869	CcSEcCtD
Salicylate-sodium—Epistaxis—Epirubicin—urinary bladder cancer	0.000157	0.000868	CcSEcCtD
Salicylate-sodium—Pruritus—Gemcitabine—urinary bladder cancer	0.000157	0.000867	CcSEcCtD
Salicylate-sodium—Nausea—Thiotepa—urinary bladder cancer	0.000157	0.000866	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Etoposide—urinary bladder cancer	0.000156	0.000863	CcSEcCtD
Salicylate-sodium—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000155	0.000856	CcSEcCtD
Salicylate-sodium—Pruritus—Fluorouracil—urinary bladder cancer	0.000154	0.000853	CcSEcCtD
Salicylate-sodium—Drowsiness—Doxorubicin—urinary bladder cancer	0.000154	0.000851	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000152	0.000842	CcSEcCtD
Salicylate-sodium—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000152	0.000839	CcSEcCtD
Salicylate-sodium—Renal failure—Doxorubicin—urinary bladder cancer	0.000151	0.000837	CcSEcCtD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000151	0.00545	CbGpPWpGaD
Salicylate-sodium—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000151	0.000834	CcSEcCtD
Salicylate-sodium—Urticaria—Etoposide—urinary bladder cancer	0.00015	0.000832	CcSEcCtD
Salicylate-sodium—Abdominal pain—Etoposide—urinary bladder cancer	0.00015	0.000828	CcSEcCtD
Salicylate-sodium—Body temperature increased—Etoposide—urinary bladder cancer	0.00015	0.000828	CcSEcCtD
Salicylate-sodium—Hepatitis—Epirubicin—urinary bladder cancer	0.000149	0.000826	CcSEcCtD
Salicylate-sodium—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000149	0.000825	CcSEcCtD
Salicylate-sodium—Tinnitus—Methotrexate—urinary bladder cancer	0.000149	0.000823	CcSEcCtD
Salicylate-sodium—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000149	0.000822	CcSEcCtD
Salicylate-sodium—Asthenia—Cisplatin—urinary bladder cancer	0.000148	0.00082	CcSEcCtD
Salicylate-sodium—Epistaxis—Doxorubicin—urinary bladder cancer	0.000145	0.000803	CcSEcCtD
Salicylate-sodium—Dizziness—Fluorouracil—urinary bladder cancer	0.000144	0.000797	CcSEcCtD
Salicylate-sodium—Diarrhoea—Cisplatin—urinary bladder cancer	0.000141	0.000782	CcSEcCtD
Salicylate-sodium—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000141	0.000781	CcSEcCtD
Salicylate-sodium—Vomiting—Gemcitabine—urinary bladder cancer	0.000141	0.000779	CcSEcCtD
Salicylate-sodium—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000141	0.00508	CbGpPWpGaD
Salicylate-sodium—Rash—Gemcitabine—urinary bladder cancer	0.00014	0.000773	CcSEcCtD
Salicylate-sodium—Dermatitis—Gemcitabine—urinary bladder cancer	0.00014	0.000772	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Etoposide—urinary bladder cancer	0.00014	0.000771	CcSEcCtD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000139	0.00503	CbGpPWpGaD
Salicylate-sodium—Tinnitus—Epirubicin—urinary bladder cancer	0.000139	0.00077	CcSEcCtD
Salicylate-sodium—Erythema—Methotrexate—urinary bladder cancer	0.000139	0.000768	CcSEcCtD
Salicylate-sodium—Headache—Gemcitabine—urinary bladder cancer	0.000139	0.000768	CcSEcCtD
Salicylate-sodium—Vomiting—Fluorouracil—urinary bladder cancer	0.000139	0.000766	CcSEcCtD
Salicylate-sodium—Hepatitis—Doxorubicin—urinary bladder cancer	0.000138	0.000764	CcSEcCtD
Salicylate-sodium—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000138	0.00076	CcSEcCtD
Salicylate-sodium—Rash—Fluorouracil—urinary bladder cancer	0.000137	0.00076	CcSEcCtD
Salicylate-sodium—Dermatitis—Fluorouracil—urinary bladder cancer	0.000137	0.000759	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000137	0.00496	CbGpPWpGaD
Salicylate-sodium—Headache—Fluorouracil—urinary bladder cancer	0.000137	0.000755	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000136	0.00493	CbGpPWpGaD
Salicylate-sodium—Dysgeusia—Methotrexate—urinary bladder cancer	0.000136	0.000752	CcSEcCtD
Salicylate-sodium—Asthenia—Etoposide—urinary bladder cancer	0.000136	0.000751	CcSEcCtD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000136	0.0049	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.000136	0.00489	CbGpPWpGaD
Salicylate-sodium—Pruritus—Etoposide—urinary bladder cancer	0.000134	0.000741	CcSEcCtD
Salicylate-sodium—Arrhythmia—Epirubicin—urinary bladder cancer	0.000133	0.000738	CcSEcCtD
Salicylate-sodium—Nausea—Gemcitabine—urinary bladder cancer	0.000132	0.000728	CcSEcCtD
Salicylate-sodium—Vomiting—Cisplatin—urinary bladder cancer	0.000131	0.000726	CcSEcCtD
Salicylate-sodium—Vision blurred—Methotrexate—urinary bladder cancer	0.000131	0.000724	CcSEcCtD
Salicylate-sodium—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000131	0.000723	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000131	0.00472	CbGpPWpGaD
Salicylate-sodium—Rash—Cisplatin—urinary bladder cancer	0.00013	0.00072	CcSEcCtD
Salicylate-sodium—Dermatitis—Cisplatin—urinary bladder cancer	0.00013	0.00072	CcSEcCtD
Salicylate-sodium—Erythema—Epirubicin—urinary bladder cancer	0.00013	0.000719	CcSEcCtD
Salicylate-sodium—Diarrhoea—Etoposide—urinary bladder cancer	0.00013	0.000716	CcSEcCtD
Salicylate-sodium—Nausea—Fluorouracil—urinary bladder cancer	0.00013	0.000716	CcSEcCtD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.00013	0.00468	CbGpPWpGaD
Salicylate-sodium—Tinnitus—Doxorubicin—urinary bladder cancer	0.000129	0.000713	CcSEcCtD
Salicylate-sodium—PTGS1—prostate gland—urinary bladder cancer	0.000129	0.0904	CbGeAlD
Salicylate-sodium—Flatulence—Epirubicin—urinary bladder cancer	0.000128	0.000708	CcSEcCtD
Salicylate-sodium—Dysgeusia—Epirubicin—urinary bladder cancer	0.000127	0.000704	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—GSTP1—urinary bladder cancer	0.000126	0.00457	CbGpPWpGaD
Salicylate-sodium—Dizziness—Etoposide—urinary bladder cancer	0.000125	0.000692	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000124	0.00449	CbGpPWpGaD
Salicylate-sodium—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000124	0.000683	CcSEcCtD
Salicylate-sodium—PTGS2—prostate gland—urinary bladder cancer	0.000123	0.0864	CbGeAlD
Salicylate-sodium—Nausea—Cisplatin—urinary bladder cancer	0.000123	0.000679	CcSEcCtD
Salicylate-sodium—Vision blurred—Epirubicin—urinary bladder cancer	0.000123	0.000678	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000121	0.00436	CbGpPWpGaD
Salicylate-sodium—Convulsion—Methotrexate—urinary bladder cancer	0.00012	0.000666	CcSEcCtD
Salicylate-sodium—Vomiting—Etoposide—urinary bladder cancer	0.00012	0.000666	CcSEcCtD
Salicylate-sodium—Erythema—Doxorubicin—urinary bladder cancer	0.00012	0.000665	CcSEcCtD
Salicylate-sodium—Rash—Etoposide—urinary bladder cancer	0.000119	0.00066	CcSEcCtD
Salicylate-sodium—Dermatitis—Etoposide—urinary bladder cancer	0.000119	0.000659	CcSEcCtD
Salicylate-sodium—Headache—Etoposide—urinary bladder cancer	0.000119	0.000656	CcSEcCtD
Salicylate-sodium—Flatulence—Doxorubicin—urinary bladder cancer	0.000119	0.000656	CcSEcCtD
Salicylate-sodium—Chest pain—Methotrexate—urinary bladder cancer	0.000118	0.000654	CcSEcCtD
Salicylate-sodium—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000118	0.000651	CcSEcCtD
Salicylate-sodium—Syncope—Epirubicin—urinary bladder cancer	0.000117	0.000645	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	0.000116	0.0042	CbGpPWpGaD
Salicylate-sodium—Palpitations—Epirubicin—urinary bladder cancer	0.000115	0.000635	CcSEcCtD
Salicylate-sodium—Confusional state—Methotrexate—urinary bladder cancer	0.000114	0.000632	CcSEcCtD
Salicylate-sodium—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000114	0.000632	CcSEcCtD
Salicylate-sodium—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000113	0.000627	CcSEcCtD
Salicylate-sodium—Vision blurred—Doxorubicin—urinary bladder cancer	0.000113	0.000627	CcSEcCtD
Salicylate-sodium—Convulsion—Epirubicin—urinary bladder cancer	0.000113	0.000623	CcSEcCtD
Salicylate-sodium—Infection—Methotrexate—urinary bladder cancer	0.000113	0.000623	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000113	0.00407	CbGpPWpGaD
Salicylate-sodium—Nausea—Etoposide—urinary bladder cancer	0.000112	0.000622	CcSEcCtD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000112	0.00404	CbGpPWpGaD
Salicylate-sodium—Chest pain—Epirubicin—urinary bladder cancer	0.000111	0.000612	CcSEcCtD
Salicylate-sodium—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000111	0.004	CbGpPWpGaD
Salicylate-sodium—Anxiety—Epirubicin—urinary bladder cancer	0.00011	0.00061	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.00011	0.00397	CbGpPWpGaD
Salicylate-sodium—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00011	0.000606	CcSEcCtD
Salicylate-sodium—PTGS1—seminal vesicle—urinary bladder cancer	0.000109	0.0765	CbGeAlD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000108	0.00391	CbGpPWpGaD
Salicylate-sodium—Anorexia—Methotrexate—urinary bladder cancer	0.000108	0.000598	CcSEcCtD
Salicylate-sodium—Syncope—Doxorubicin—urinary bladder cancer	0.000108	0.000597	CcSEcCtD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000108	0.00389	CbGpPWpGaD
Salicylate-sodium—Confusional state—Epirubicin—urinary bladder cancer	0.000107	0.000592	CcSEcCtD
Salicylate-sodium—Palpitations—Doxorubicin—urinary bladder cancer	0.000106	0.000588	CcSEcCtD
Salicylate-sodium—Oedema—Epirubicin—urinary bladder cancer	0.000106	0.000587	CcSEcCtD
Salicylate-sodium—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000106	0.000587	CcSEcCtD
Salicylate-sodium—Hypotension—Methotrexate—urinary bladder cancer	0.000106	0.000586	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000106	0.00382	CbGpPWpGaD
Salicylate-sodium—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000106	0.000585	CcSEcCtD
Salicylate-sodium—Infection—Epirubicin—urinary bladder cancer	0.000105	0.000583	CcSEcCtD
Salicylate-sodium—Shock—Epirubicin—urinary bladder cancer	0.000104	0.000577	CcSEcCtD
Salicylate-sodium—Convulsion—Doxorubicin—urinary bladder cancer	0.000104	0.000576	CcSEcCtD
Salicylate-sodium—PTGS2—seminal vesicle—urinary bladder cancer	0.000104	0.0731	CbGeAlD
Salicylate-sodium—Tachycardia—Epirubicin—urinary bladder cancer	0.000104	0.000573	CcSEcCtD
Salicylate-sodium—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000103	0.000567	CcSEcCtD
Salicylate-sodium—Chest pain—Doxorubicin—urinary bladder cancer	0.000102	0.000566	CcSEcCtD
Salicylate-sodium—Anxiety—Doxorubicin—urinary bladder cancer	0.000102	0.000564	CcSEcCtD
Salicylate-sodium—Paraesthesia—Methotrexate—urinary bladder cancer	0.000102	0.000563	CcSEcCtD
Salicylate-sodium—Anorexia—Epirubicin—urinary bladder cancer	0.000101	0.000559	CcSEcCtD
Salicylate-sodium—Dyspnoea—Methotrexate—urinary bladder cancer	0.000101	0.000559	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000101	0.00364	CbGpPWpGaD
Salicylate-sodium—Somnolence—Methotrexate—urinary bladder cancer	0.000101	0.000557	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.0001	0.00361	CbGpPWpGaD
Salicylate-sodium—Dyspepsia—Methotrexate—urinary bladder cancer	9.99e-05	0.000552	CcSEcCtD
Salicylate-sodium—Hypotension—Epirubicin—urinary bladder cancer	9.92e-05	0.000548	CcSEcCtD
Salicylate-sodium—Confusional state—Doxorubicin—urinary bladder cancer	9.9e-05	0.000547	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	9.87e-05	0.00356	CbGpPWpGaD
Salicylate-sodium—Decreased appetite—Methotrexate—urinary bladder cancer	9.86e-05	0.000545	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	9.84e-05	0.00355	CbGpPWpGaD
Salicylate-sodium—Anaphylactic shock—Doxorubicin—urinary bladder cancer	9.82e-05	0.000543	CcSEcCtD
Salicylate-sodium—Oedema—Doxorubicin—urinary bladder cancer	9.82e-05	0.000543	CcSEcCtD
Salicylate-sodium—Fatigue—Methotrexate—urinary bladder cancer	9.78e-05	0.000541	CcSEcCtD
Salicylate-sodium—Infection—Doxorubicin—urinary bladder cancer	9.76e-05	0.000539	CcSEcCtD
Salicylate-sodium—Pain—Methotrexate—urinary bladder cancer	9.7e-05	0.000536	CcSEcCtD
Salicylate-sodium—Shock—Doxorubicin—urinary bladder cancer	9.66e-05	0.000534	CcSEcCtD
Salicylate-sodium—Tachycardia—Doxorubicin—urinary bladder cancer	9.59e-05	0.00053	CcSEcCtD
Salicylate-sodium—Paraesthesia—Epirubicin—urinary bladder cancer	9.53e-05	0.000527	CcSEcCtD
Salicylate-sodium—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.5e-05	0.000525	CcSEcCtD
Salicylate-sodium—PTGS1—epithelium—urinary bladder cancer	9.47e-05	0.0664	CbGeAlD
Salicylate-sodium—Dyspnoea—Epirubicin—urinary bladder cancer	9.46e-05	0.000523	CcSEcCtD
Salicylate-sodium—Somnolence—Epirubicin—urinary bladder cancer	9.44e-05	0.000522	CcSEcCtD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	9.43e-05	0.00341	CbGpPWpGaD
Salicylate-sodium—Anorexia—Doxorubicin—urinary bladder cancer	9.36e-05	0.000518	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Methotrexate—urinary bladder cancer	9.35e-05	0.000517	CcSEcCtD
Salicylate-sodium—Dyspepsia—Epirubicin—urinary bladder cancer	9.34e-05	0.000517	CcSEcCtD
Salicylate-sodium—Gastrointestinal pain—Methotrexate—urinary bladder cancer	9.28e-05	0.000513	CcSEcCtD
Salicylate-sodium—Decreased appetite—Epirubicin—urinary bladder cancer	9.23e-05	0.00051	CcSEcCtD
Salicylate-sodium—Hypotension—Doxorubicin—urinary bladder cancer	9.18e-05	0.000507	CcSEcCtD
Salicylate-sodium—Fatigue—Epirubicin—urinary bladder cancer	9.15e-05	0.000506	CcSEcCtD
Salicylate-sodium—PTGS1—smooth muscle tissue—urinary bladder cancer	9.12e-05	0.064	CbGeAlD
Salicylate-sodium—Constipation—Epirubicin—urinary bladder cancer	9.08e-05	0.000502	CcSEcCtD
Salicylate-sodium—Pain—Epirubicin—urinary bladder cancer	9.08e-05	0.000502	CcSEcCtD
Salicylate-sodium—PTGS2—epithelium—urinary bladder cancer	9.05e-05	0.0635	CbGeAlD
Salicylate-sodium—Urticaria—Methotrexate—urinary bladder cancer	9.01e-05	0.000498	CcSEcCtD
Salicylate-sodium—Abdominal pain—Methotrexate—urinary bladder cancer	8.97e-05	0.000496	CcSEcCtD
Salicylate-sodium—Body temperature increased—Methotrexate—urinary bladder cancer	8.97e-05	0.000496	CcSEcCtD
Salicylate-sodium—Paraesthesia—Doxorubicin—urinary bladder cancer	8.82e-05	0.000488	CcSEcCtD
Salicylate-sodium—PTGS1—renal system—urinary bladder cancer	8.78e-05	0.0616	CbGeAlD
Salicylate-sodium—Dyspnoea—Doxorubicin—urinary bladder cancer	8.76e-05	0.000484	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Epirubicin—urinary bladder cancer	8.75e-05	0.000484	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	8.74e-05	0.00316	CbGpPWpGaD
Salicylate-sodium—Somnolence—Doxorubicin—urinary bladder cancer	8.73e-05	0.000483	CcSEcCtD
Salicylate-sodium—PTGS2—smooth muscle tissue—urinary bladder cancer	8.72e-05	0.0612	CbGeAlD
Salicylate-sodium—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.68e-05	0.00048	CcSEcCtD
Salicylate-sodium—Dyspepsia—Doxorubicin—urinary bladder cancer	8.65e-05	0.000478	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	8.58e-05	0.0031	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	8.55e-05	0.00309	CbGpPWpGaD
Salicylate-sodium—Decreased appetite—Doxorubicin—urinary bladder cancer	8.54e-05	0.000472	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	8.5e-05	0.00307	CbGpPWpGaD
Salicylate-sodium—Fatigue—Doxorubicin—urinary bladder cancer	8.47e-05	0.000468	CcSEcCtD
Salicylate-sodium—Urticaria—Epirubicin—urinary bladder cancer	8.43e-05	0.000466	CcSEcCtD
Salicylate-sodium—Constipation—Doxorubicin—urinary bladder cancer	8.4e-05	0.000464	CcSEcCtD
Salicylate-sodium—Pain—Doxorubicin—urinary bladder cancer	8.4e-05	0.000464	CcSEcCtD
Salicylate-sodium—PTGS2—renal system—urinary bladder cancer	8.4e-05	0.0589	CbGeAlD
Salicylate-sodium—Body temperature increased—Epirubicin—urinary bladder cancer	8.39e-05	0.000464	CcSEcCtD
Salicylate-sodium—Abdominal pain—Epirubicin—urinary bladder cancer	8.39e-05	0.000464	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Methotrexate—urinary bladder cancer	8.36e-05	0.000462	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	8.34e-05	0.00301	CbGpPWpGaD
Salicylate-sodium—PTGS2—urethra—urinary bladder cancer	8.25e-05	0.0578	CbGeAlD
Salicylate-sodium—Asthenia—Methotrexate—urinary bladder cancer	8.14e-05	0.00045	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Doxorubicin—urinary bladder cancer	8.09e-05	0.000447	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	8.07e-05	0.00291	CbGpPWpGaD
Salicylate-sodium—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	8.03e-05	0.000444	CcSEcCtD
Salicylate-sodium—Pruritus—Methotrexate—urinary bladder cancer	8.03e-05	0.000444	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Epirubicin—urinary bladder cancer	7.82e-05	0.000432	CcSEcCtD
Salicylate-sodium—Urticaria—Doxorubicin—urinary bladder cancer	7.8e-05	0.000431	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	7.77e-05	0.0028	CbGpPWpGaD
Salicylate-sodium—Abdominal pain—Doxorubicin—urinary bladder cancer	7.77e-05	0.000429	CcSEcCtD
Salicylate-sodium—Body temperature increased—Doxorubicin—urinary bladder cancer	7.77e-05	0.000429	CcSEcCtD
Salicylate-sodium—Diarrhoea—Methotrexate—urinary bladder cancer	7.76e-05	0.000429	CcSEcCtD
Salicylate-sodium—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	7.75e-05	0.0028	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	7.67e-05	0.00277	CbGpPWpGaD
Salicylate-sodium—Asthenia—Epirubicin—urinary bladder cancer	7.62e-05	0.000421	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	7.61e-05	0.00275	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	7.56e-05	0.00273	CbGpPWpGaD
Salicylate-sodium—Pruritus—Epirubicin—urinary bladder cancer	7.51e-05	0.000415	CcSEcCtD
Salicylate-sodium—Dizziness—Methotrexate—urinary bladder cancer	7.5e-05	0.000415	CcSEcCtD
Salicylate-sodium—PTGS1—Metabolism—GSTO2—urinary bladder cancer	7.34e-05	0.00265	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—NAT1—urinary bladder cancer	7.34e-05	0.00265	CbGpPWpGaD
Salicylate-sodium—Diarrhoea—Epirubicin—urinary bladder cancer	7.26e-05	0.000401	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Doxorubicin—urinary bladder cancer	7.24e-05	0.0004	CcSEcCtD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.22e-05	0.00261	CbGpPWpGaD
Salicylate-sodium—Vomiting—Methotrexate—urinary bladder cancer	7.21e-05	0.000399	CcSEcCtD
Salicylate-sodium—Rash—Methotrexate—urinary bladder cancer	7.15e-05	0.000395	CcSEcCtD
Salicylate-sodium—Dermatitis—Methotrexate—urinary bladder cancer	7.15e-05	0.000395	CcSEcCtD
Salicylate-sodium—Headache—Methotrexate—urinary bladder cancer	7.11e-05	0.000393	CcSEcCtD
Salicylate-sodium—Asthenia—Doxorubicin—urinary bladder cancer	7.05e-05	0.00039	CcSEcCtD
Salicylate-sodium—PTGS1—female reproductive system—urinary bladder cancer	7.03e-05	0.0493	CbGeAlD
Salicylate-sodium—Dizziness—Epirubicin—urinary bladder cancer	7.02e-05	0.000388	CcSEcCtD
Salicylate-sodium—PTGS2—Disease—GSTO2—urinary bladder cancer	6.96e-05	0.00251	CbGpPWpGaD
Salicylate-sodium—Pruritus—Doxorubicin—urinary bladder cancer	6.95e-05	0.000384	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	6.82e-05	0.00246	CbGpPWpGaD
Salicylate-sodium—Vomiting—Epirubicin—urinary bladder cancer	6.75e-05	0.000373	CcSEcCtD
Salicylate-sodium—Nausea—Methotrexate—urinary bladder cancer	6.74e-05	0.000372	CcSEcCtD
Salicylate-sodium—PTGS2—female reproductive system—urinary bladder cancer	6.72e-05	0.0472	CbGeAlD
Salicylate-sodium—Diarrhoea—Doxorubicin—urinary bladder cancer	6.72e-05	0.000371	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.72e-05	0.00243	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	6.72e-05	0.00243	CbGpPWpGaD
Salicylate-sodium—Rash—Epirubicin—urinary bladder cancer	6.69e-05	0.00037	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.69e-05	0.00242	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	6.69e-05	0.00241	CbGpPWpGaD
Salicylate-sodium—Dermatitis—Epirubicin—urinary bladder cancer	6.69e-05	0.00037	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.66e-05	0.00241	CbGpPWpGaD
Salicylate-sodium—Headache—Epirubicin—urinary bladder cancer	6.65e-05	0.000368	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	6.52e-05	0.00235	CbGpPWpGaD
Salicylate-sodium—Dizziness—Doxorubicin—urinary bladder cancer	6.5e-05	0.000359	CcSEcCtD
Salicylate-sodium—PTGS1—vagina—urinary bladder cancer	6.36e-05	0.0446	CbGeAlD
Salicylate-sodium—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	6.35e-05	0.00229	CbGpPWpGaD
Salicylate-sodium—Nausea—Epirubicin—urinary bladder cancer	6.31e-05	0.000349	CcSEcCtD
Salicylate-sodium—Vomiting—Doxorubicin—urinary bladder cancer	6.25e-05	0.000345	CcSEcCtD
Salicylate-sodium—Rash—Doxorubicin—urinary bladder cancer	6.19e-05	0.000342	CcSEcCtD
Salicylate-sodium—Dermatitis—Doxorubicin—urinary bladder cancer	6.19e-05	0.000342	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	6.18e-05	0.00223	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	6.17e-05	0.00223	CbGpPWpGaD
Salicylate-sodium—Headache—Doxorubicin—urinary bladder cancer	6.15e-05	0.00034	CcSEcCtD
Salicylate-sodium—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	6.15e-05	0.00222	CbGpPWpGaD
Salicylate-sodium—PTGS2—vagina—urinary bladder cancer	6.08e-05	0.0427	CbGeAlD
Salicylate-sodium—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	6.05e-05	0.00218	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	6e-05	0.00217	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.84e-05	0.00211	CbGpPWpGaD
Salicylate-sodium—Nausea—Doxorubicin—urinary bladder cancer	5.83e-05	0.000322	CcSEcCtD
Salicylate-sodium—PTGS2—Metabolism—GSTO2—urinary bladder cancer	5.83e-05	0.00211	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—NAT1—urinary bladder cancer	5.83e-05	0.00211	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.77e-05	0.00208	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.73e-05	0.00207	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	5.71e-05	0.00206	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PRSS3—urinary bladder cancer	5.57e-05	0.00201	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—SLC19A1—urinary bladder cancer	5.41e-05	0.00195	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	5.33e-05	0.00193	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PRSS3—urinary bladder cancer	5.28e-05	0.00191	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	5.25e-05	0.0019	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	5.1e-05	0.00184	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HDAC4—urinary bladder cancer	5.03e-05	0.00182	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	4.98e-05	0.0018	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.89e-05	0.00177	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	4.8e-05	0.00173	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	4.75e-05	0.00171	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	4.53e-05	0.00164	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.46e-05	0.00161	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—TYMP—urinary bladder cancer	4.45e-05	0.00161	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PRSS3—urinary bladder cancer	4.42e-05	0.0016	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.32e-05	0.00156	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.27e-05	0.00154	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	4.18e-05	0.00151	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.18e-05	0.00151	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.17e-05	0.00151	CbGpPWpGaD
Salicylate-sodium—PTGS1—lymph node—urinary bladder cancer	4.11e-05	0.0289	CbGeAlD
Salicylate-sodium—PTGS1—Metabolism—NAT2—urinary bladder cancer	4.02e-05	0.00145	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—LIG1—urinary bladder cancer	4e-05	0.00144	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.98e-05	0.00144	CbGpPWpGaD
Salicylate-sodium—PTGS2—lymph node—urinary bladder cancer	3.93e-05	0.0276	CbGeAlD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.87e-05	0.0014	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.54e-05	0.00128	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—TYMP—urinary bladder cancer	3.53e-05	0.00128	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—RRM2—urinary bladder cancer	3.47e-05	0.00125	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.47e-05	0.00125	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.39e-05	0.00123	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.39e-05	0.00122	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.23e-05	0.00117	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—HPGDS—urinary bladder cancer	3.22e-05	0.00116	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ENO2—urinary bladder cancer	3.22e-05	0.00116	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.2e-05	0.00116	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.2e-05	0.00115	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—NAT2—urinary bladder cancer	3.19e-05	0.00115	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTT1—urinary bladder cancer	3.12e-05	0.00113	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.07e-05	0.00111	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—ENO2—urinary bladder cancer	3.05e-05	0.0011	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—RBX1—urinary bladder cancer	2.89e-05	0.00104	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.85e-05	0.00103	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—RRM2—urinary bladder cancer	2.76e-05	0.000996	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—NQO1—urinary bladder cancer	2.59e-05	0.000936	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—JAG1—urinary bladder cancer	2.59e-05	0.000934	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.55e-05	0.000922	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.55e-05	0.000922	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.54e-05	0.000917	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.52e-05	0.000908	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.48e-05	0.000894	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.44e-05	0.000881	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.19e-05	0.000792	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.16e-05	0.000781	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.09e-05	0.000756	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—NQO1—urinary bladder cancer	2.06e-05	0.000743	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—TYMS—urinary bladder cancer	2.01e-05	0.000726	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.99e-05	0.000718	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.99e-05	0.000718	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.9e-05	0.000687	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—NCOR1—urinary bladder cancer	1.88e-05	0.00068	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.87e-05	0.000675	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—ERCC2—urinary bladder cancer	1.77e-05	0.00064	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.76e-05	0.000634	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.74e-05	0.000629	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.72e-05	0.00062	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—MTHFR—urinary bladder cancer	1.66e-05	0.000601	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.66e-05	0.0006	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—TERT—urinary bladder cancer	1.66e-05	0.0006	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.6e-05	0.000576	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.58e-05	0.00057	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.58e-05	0.00057	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—FGFR3—urinary bladder cancer	1.52e-05	0.00055	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.51e-05	0.000546	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.48e-05	0.000536	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.42e-05	0.000514	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.39e-05	0.000504	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.37e-05	0.000494	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CREBBP—urinary bladder cancer	1.3e-05	0.000468	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—RHOA—urinary bladder cancer	1.17e-05	0.000424	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.13e-05	0.000408	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.12e-05	0.000405	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.09e-05	0.000392	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—ERBB2—urinary bladder cancer	1.09e-05	0.000392	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PTEN—urinary bladder cancer	9.77e-06	0.000353	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—EP300—urinary bladder cancer	9.32e-06	0.000336	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CDKN1A—urinary bladder cancer	9.28e-06	0.000335	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PTEN—urinary bladder cancer	9.26e-06	0.000334	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—EP300—urinary bladder cancer	8.83e-06	0.000319	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—SRC—urinary bladder cancer	8.59e-06	0.00031	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PTEN—urinary bladder cancer	7.76e-06	0.00028	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—MYC—urinary bladder cancer	7.7e-06	0.000278	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—EGFR—urinary bladder cancer	7.53e-06	0.000272	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—EP300—urinary bladder cancer	7.4e-06	0.000267	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—KRAS—urinary bladder cancer	7.11e-06	0.000257	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HRAS—urinary bladder cancer	6.05e-06	0.000218	CbGpPWpGaD
